• DOI:10.1080/21678421.2018.1425455
Corpus ID: 4627647

Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective

@article{Yeo2018DiscussingEW,
  title={Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective},
  author={Crystal Jing Jing Yeo and Z. Simmons},
  journal={Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration},
  year={2018},
  volume={19},
  pages={167 - 172}
}

Crystal Jing Jing Yeo, Z. Simmons

Published 2018

Psychology, Medicine

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Abstract The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare… CONTINUE READING

View on Taylor & Francis

bellvitgehospital.cat

Save to Library

Create Alert

Cite

Launch Research Feed